Literature DB >> 16722238

The dopamine transporter: a vigilant border control for psychostimulant action.

J M Williams1, A Galli.   

Abstract

Neurotransmission within the mesocorticolimbic dopamine system has remained the central focus of investigation into the molecular, cellular and behavioral properties of psychostimulants for nearly three decades. The primary means by which dopamine transmission in the synapse is terminated is via the dopamine transporter (DAT), the presynaptic plasmalemmal protein that is responsible for the reuptake of released dopamine. Numerous abused as well as clinically important drugs have important pharmacological interactions with DAT. In general, these compounds fall into two categories: those that block dopamine transport (e.g., cocaine, methylphenidate) and those that serve as substrates for transport [e.g., dopamine, amphetamine and 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy")]. Recent data from in vitro and in vivo studies have suggested that DAT, like other biogenic amine transporters, share several characteristics with classical ligand-gated ion channels. In addition, substrates for transport promote redistribution of DAT away from the plasma membrane, while transport inhibitors such as cocaine disrupt this process. In addition, presynaptic autoreceptors for dopamine have been implicated in the modulation of DAT surface expression and function. The present chapter summarizes some of the recent discoveries pertaining to the electrogenic properties of DAT and their potential relevance to the effects of amphetamine-like stimulants on DAT function. Although there are a number of intracellular and extracellular modulatory influences on dopamine clearance that may play particular roles in psychostimulant action, we specifically focus on the differential direct modulation of DAT function by transport substrates and inhibitors, and we also discusses the role of presynaptic D2 receptors in transport regulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722238     DOI: 10.1007/3-540-29784-7_11

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  21 in total

1.  Akt-dependent and isoform-specific regulation of dopamine transporter cell surface expression.

Authors:  Nicole K Speed; Heinrich J G Matthies; J Phillip Kennedy; Roxanne A Vaughan; Jonathan A Javitch; Scott J Russo; Craig W Lindsley; Kevin Niswender; Aurelio Galli
Journal:  ACS Chem Neurosci       Date:  2010-05-25       Impact factor: 4.418

2.  Prenatal amphetamine exposure effects on dopaminergic receptors and transporter in postnatal rats.

Authors:  Gonzalo Flores; María de Jesús Gómez-Villalobos; Leonardo Rodríguez-Sosa
Journal:  Neurochem Res       Date:  2011-05-25       Impact factor: 3.996

3.  meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Seth D Norrholm; John P Culver; Marhaba Hojahmat; Joshua S Beckmann; Steven B Harrod; Agripina G Deaciuc; Michael T Bardo; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

4.  Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.

Authors:  Amy K Wagner; Laura L Drewencki; Xiangbai Chen; F Ryan Santos; Amina S Khan; Rashed Harun; Gonzalo E Torres; Adrian C Michael; C Edward Dixon
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

5.  Low and high cocaine locomotor responding male Sprague-Dawley rats differ in rapid cocaine-induced regulation of striatal dopamine transporter function.

Authors:  Bruce H Mandt; Nancy R Zahniser
Journal:  Neuropharmacology       Date:  2009-12-04       Impact factor: 5.250

6.  Neurotransmission and bipolar disorder: a systematic family-based association study.

Authors:  Jiajun Shi; Judith A Badner; Eiji Hattori; James B Potash; Virginia L Willour; Francis J McMahon; Elliot S Gershon; Chunyu Liu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 7.  Imaging dopamine's role in drug abuse and addiction.

Authors:  N D Volkow; J S Fowler; G J Wang; R Baler; F Telang
Journal:  Neuropharmacology       Date:  2008-06-03       Impact factor: 5.250

8.  Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study.

Authors:  Jason M Williams; Dejan Milatovic; John C Gore; Michael Aschner; Malcolm J Avison
Journal:  Toxicol Sci       Date:  2010-01-08       Impact factor: 4.849

9.  Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects.

Authors:  Estefanía Moreno; David Moreno-Delgado; Gemma Navarro; Hanne M Hoffmann; Silvia Fuentes; Santi Rosell-Vilar; Paola Gasperini; Mar Rodríguez-Ruiz; Mireia Medrano; Josefa Mallol; Antoni Cortés; Vicent Casadó; Carme Lluís; Sergi Ferré; Jordi Ortiz; Enric Canela; Peter J McCormick
Journal:  J Neurosci       Date:  2014-03-05       Impact factor: 6.167

10.  Zebrafish reward mutants reveal novel transcripts mediating the behavioral effects of amphetamine.

Authors:  Katharine J Webb; William Hj Norton; Dietrich Trümbach; Annemarie H Meijer; Jovica Ninkovic; Stefanie Topp; Daniel Heck; Carsten Marr; Wolfgang Wurst; Fabian J Theis; Herman P Spaink; Laure Bally-Cuif
Journal:  Genome Biol       Date:  2009-07-31       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.